ENLV
Enlivex Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.11
−4.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
Market Cap
$19.32M
MomentumView details →
1D Return
−4.74%
YTD Return
−89.53%
RSI (14)
15.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
Market Cap
$19.32M
RSI (14)
15.8
MomentumView details →
1D Return
−4.74%
YTD Return
−89.53%
SummaryUpdated Dec 1, 2025
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is an Israeli clinical-stage biotechnology company founded in 2005 and headquartered in Nes Ziona, Israel. The company went public in 2014 and specializes in developing innovative cell-based immunotherapies focused on macrophage reprogramming. Enlivex operates as a pure-play research and development company with no current revenue, dedicating its resources to advancing its lead therapeutic candidate through clinical trials for life-threatening conditions including sepsis and solid tumors.
Similar companies
Latest newsMore news →
Enlivex, a Nasdaq-listed biotech company, is seeking shareholder approval to authorize up to $800 million in financing, potentially increasing share count by up to 951%, with proceeds primarily used to acquire the RAIN crypto token for treasury purposes.35d agoEnlivex announced a private placement of $400,000,000 of ordinary shares to a single institutional investor.38d ago